Monique Kaur Atwal, MD
Psychiatry · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Atwal’s office at (559) 600-9180 to ask if they take your plan before you enroll.
California Medical Board record
Licence A179742 · Current
Licensed to practise in California · since 2022 · expires 2028-08-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Psychiatry
Drugs they prescribed that Part D paid
$6,427
Pharmacies billed $6,427 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 63) in 2024. At or below the middle of the specialty; the typical psychiatry & neurology clinician is at 0%.
60 generic and fewer than 11 brand-name prescriptions · $6,427 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 63 | None | 0% (0) | None | $6,427 |
| 2023 | 47 | None | 0% (0) | None | $8,201 |
| 2022 | 81 | None | 0% (0) | 14% | $14,722 |
| 2021 | 30 | None | 0% (0) | None | $5,268 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
$638 in 2025
A payment is not proof that care is biased.
| Neurocrine BioSciences | Ingrezza | $265 | 2 payments
|
| Alkermes | Lybalvi | $130 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $127 | 1 payment
|
| Otsuka America Pharmaceutical | Abilify Maintena | $117 | 1 payment
|
See all 5 published payments
| Otsuka America Pharmaceutical | Meals · 2025-07-08 | Abilify Maintena | $117 |
| Neurocrine BioSciences | Meals · 2025-05-14 | Ingrezza | $140 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-29 | Cobenfy | $127 |
| Alkermes | Meals · 2025-03-18 | Lybalvi | $130 |
| Neurocrine BioSciences | Meals · 2025-01-22 | Ingrezza | $125 |
Professional record
- NPI
- 1770045924
- Licence
- CA A179742California A179742: Current · expires 2028-08-31
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 2625 E Divisadero St, Fresno, CA, 93721
- NPI first listed
- 2019-04-04
- NPI last updated
- 2024-08-22
- NPI record certified
- 2024-08-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1060 W Sierra Ave Ste 105, Fresno, CA, 93711